过去几年，早期乳腺癌（BC）的治疗见证了新辅助治疗使用的增加，以及新辅助治疗后全身治疗的显着重塑，许多有争议的临床情况的演变需要达成共识。在第 14 届会议期间乳腺妇科和免疫肿瘤学国际癌症会议于 2022 年在埃及举行，来自 13 个国家的 44 名 BC 专家组成的小组对有关新/辅助治疗环境中存在争议的挑战的声明进行了投票。这些建议随后根据最新出现的数据进行了更新。使用修改后的德尔菲法来达成这一共识。当 ≥75% 的选民选择答案时即可达成共识。共识建议讨论了早期 BC 新辅助治疗中的不同升级和降级策略。这些建议概括了现有的临床证据和专家意见，以实现个体化患者管理和优化治疗结果。 63% 的声明 (52/83) 达成共识，并且澄清了每项声明背后的基本原理。© 2024 美国癌症协会。

The management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the systemic therapy postneoadjuvant treatment in the last few years, with the evolution of many controversial clinical situations that require consensus.During the 14th Breast-Gynecological and Immuno-Oncology International Cancer Conference held in Egypt in 2022, a panel of 44 BC experts from 13 countries voted on statements concerning debatable challenges in the neo/adjuvant treatment setting. The recommendations were subsequently updated based on the most recent data emerging. A modified Delphi approach was used to develop this consensus. A consensus was achieved when ≥75% of voters selected an answer.The consensus recommendations addressed different escalation and de-escalation strategies in the setting of neoadjuvant therapy for early BC. The recommendations recapitulate the available clinical evidence and expert opinion to individualize patient management and optimize therapy outcomes. Consensus was reached in 63% of the statements (52/83), and the rationale behind each statement was clarified.© 2024 American Cancer Society.